Michael Paveloff, MD
Ophthalmology · Santa Barbara, CANPI 1396756847
Payments from drug & device makers
Across 243 payments — averaging $54.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$6K
- Sight Sciences, Inc.$1K
- Alcon Research LLC$1K
- Glaukos Corporation$1K
- Ivantis, Inc$445
- AbbVie$424
- plus $3K from 22 others
What the payments were for
- Consulting fees$1,2259%
- Travel & lodging$120%
- Food & beverage$11,92591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 94 | $5,858 |
| Sight Sciences, Inc. | 26 | $1,381 |
| Alcon Research LLC | 2 | $1,225 |
| Glaukos Corporation | 10 | $1,012 |
| Ivantis, Inc | 6 | $445 |
| AbbVie(2 entities) | 15 | $424 |
| Sun Pharmaceutical Industries Inc. | 11 | $354 |
| Nova Eye, Inc. | 2 | $342 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $316 |
| Kala Pharmaceuticals, Inc. | 14 | $289 |
| Apellis Pharmaceuticals, Inc. | 2 | $186 |
| Bausch & Lomb Americas Inc. | 7 | $156 |
| Novartis | 7 | $154 |
| Eyevance Pharmaceuticals LLC | 7 | $136 |
| Regeneron Healthcare Solutions, Inc. | 1 | $112 |
| Ocular Therapeutix, Inc. | 6 | $109 |
| Aerie Pharmaceuticals, Inc. | 1 | $102 |
| Neurotech Pharmaceuticals, Inc. | 1 | $101 |
| Dompe US, Inc. | 4 | $99 |
| Regeneron | 1 | $99 |
| Tarsus Pharmaceuticals, Inc. | 3 | $66 |
| Shire North American Group Inc | 3 | $46 |
| NEW World Medical,inc. | 3 | $41 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,344
- NGENUITY$1,225
- ReSTOR$471
- OMNI$454
- Centurion$426
- ARGOS$410
- AcrySof IQ PanOptix$358
- Hydrus$259
- PanOptix$254
- iStent inject Trabecular Micro-Bypass Stent System$248
- Hydrus Microstent$239
- OMNI(R) SURGICAL SYSTEM (US)$238
- AcrySof IQ PanOptix UV IOL$215
- iDoseTR$174
- iStent Trabecular Micro-Bypass System Model iS3$170
- iStent inject W$139
- Unity$127
- LenSx$124
- EYLEA$112
- ENVISTA TORIC$112
How this compares
$13,162 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 149 | $133,319 |
| LumiganBimatoprost | 147 | $59,627 |
| IlevroNepafenac | 66 | $24,268 |
| Cyclosporine | 49 | $23,271 |
| VyzultaLatanoprostene Bunod | 42 | $19,355 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $16,437 |
| ProlensaBromfenac Sodium | 46 | $15,817 |
| FlarexFluorometholone Acetate | 89 | $11,232 |
| Travoprost | 37 | $9,040 |
| Lotemax SmLoteprednol Etabonate | 36 | $8,985 |
| Timolol Maleate | 211 | $8,317 |
| Brimonidine Tartrate | 119 | $7,235 |
| MoxifloxacinMoxifloxacin Hcl | 368 | $6,905 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $6,751 |
| Alphagan PBrimonidine Tartrate | 26 | $6,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $424 | $215,861369 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Zylet | $316 | $29,56796 claims |
| NovartisIlevro | $154 | $24,26866 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $156 | $19,35542 claims |
| Eyevance Pharmaceuticals LLCFlarex, Tobradex St | $136 | $17,629117 claims |
| AlconSimbrinza | $5,858 | $6,75131 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $102 | $5,52617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Santa Barbara
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.